Barcelona, Spain : 9 - 11 October 2017
We are living in very exciting times in the context of molecular oncology and in particular in the field of immuno-oncology. A deeper understanding of the molecular mechanisms involved in the interaction between the tumour and the immune system is revealing an attractive set of novel therapeutic approaches to treat cancer. With some pronounced recent successes in this field, this is fuelling aggressive investigation, leading to new questions and challenges.
In this conference, we will learn about the most recent advances in the field of immunotherapy from the basic science to clinical studies including the identification of novel targets; an improved understanding of the mechanisms of action of therapeutic interventions; as well as discussions about biomarkers of response to treatment and mechanisms of intrinsic and acquired resistance to immunotherapy.
The target audience for this conference is basic and translational scientists and clinicians, both senior and young investigators that want to have a broad and detailed overview of the most recent advances in the field of immunotherapy.
Innate immune response
Microbioma and the immune system
CAR T cells
Biomarkers of response to immunotherapy
Mechanisms of resistance to immunotherapy
Scientific Programme Committee: Johanna Joyce, Ignacio Melero, Daniel Peeper, Joan Seoane (Chair)
Defence is the Best Attack: Immuno-Oncology Breakthroughs, Barcelona, Spain, 09/10/2017-11/10/2017, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 12 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Bursary application deadline:
31 July 2017
Abstract submission deadline:
31 July 2017
01 September 2017
La Pedrera, Gaudí's famous building in the centre of Barcelona.
This is considered an out of date browser. This website has been developed with modern browsers in mind to allow it to display at its best in a wide variety of viewing situations - including mobile viewing. But we haven't supported older browsers like IE8. Please upgrade to the latest version of Internet Explorer - or try Mozilla Firefox or Google Chrome. Both are excellent browsers.